This individual patient expanded access IND is requested for a patient diagnosed with LMNA-related congenital muscular dystrophy (L-CMD). In this expanded access, the patient will receive the investigational product through 14 intravenous infusions, followed by Follow-Up visit and an End of Study.

HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.

An Expanded Access IND to Evaluate the Safety and Efficacy of Autologous HBadMSCs for the Treatment of a Single Pediatric Patient With Congenital Muscular Dystrophy.

Treatment Trials

Focus your search

HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.

Description

Conditions